Church is widely recognized for contributions that have shaped several major branches of contemporary biomedicine. His career has included pioneering work in genome sequencing, genome editing, synthetic biology, gene therapy, cellular reprogramming, artificial intelligence-based protein engineering, and the study of aging. He has also been involved in landmark initiatives such as the Human Genome Project, the Personal Genome Project, the BRAIN Initiative, and Genome Project-write. Together, these efforts have helped transform DNA from a biological molecule studied primarily through observation into an increasingly programmable platform. Modern sequencing can now read genetic information at enormous scale, while editing technologies can alter selected sequences and synthetic biology can assemble new genetic systems for research or therapeutic use.

That convergence is particularly important to longevity research, where scientists are investigating the molecular mechanisms that cause tissues and organs to lose resilience over time. Aging is not controlled by a single gene or pathway. Instead, it involves interacting processes that include the accumulation of DNA damage, epigenetic changes that disrupt gene regulation, mitochondrial dysfunction, chronic inflammation, loss of protein quality control, cellular senescence, stem-cell exhaustion, and alterations in intercellular communication. These mechanisms can reinforce one another, gradually reducing an organism’s ability to repair damage and maintain stable physiological function. Church’s participation at ARDD 2026 is expected to focus attention on how emerging technologies might intervene in these systems, either by correcting damage, resetting cellular states, replacing dysfunctional cells, or improving the body’s capacity for repair.

One of the most closely watched possibilities is cellular reprogramming. In experimental systems, combinations of transcription factors can push mature cells toward a more developmentally flexible state, sometimes restoring molecular features associated with youth while preserving aspects of cellular identity. The challenge is to achieve rejuvenation without causing uncontrolled proliferation or loss of tissue function. Gene therapy offers another route, using engineered viral vectors or other delivery systems to introduce, silence, or regulate genetic instructions inside selected cells. Such approaches could potentially target age-related disorders, although delivery, immune reactions, durability, dosage, and safety remain major barriers. Advances in protein engineering and artificial intelligence may also accelerate the discovery of therapeutic molecules capable of modulating difficult biological targets.

Church joins ARDD at a moment when longevity science is moving from exploratory laboratory research toward increasingly organized drug-development programs. Pharmaceutical and biotechnology companies are investigating interventions designed to influence senescent cells, metabolic regulation, inflammation, DNA repair, mitochondrial performance, and other biological processes associated with aging. The field’s central ambition is not simply to extend lifespan, but to lengthen healthspan—the period during which people remain physically capable, cognitively functional, and free from disabling disease. Achieving that goal will require rigorous clinical trials capable of demonstrating meaningful improvements in health outcomes rather than relying only on changes in molecular biomarkers. Researchers must also determine whether an intervention that benefits one organ or pathway can produce durable advantages across the entire body.

The meeting will therefore examine a question that has moved increasingly into mainstream biomedical discussion: how close is science to a genuine longevity revolution? The answer depends on whether promising findings in cells and laboratory animals can be translated into safe, reproducible effects in humans. Biological aging differs across tissues and individuals, and the biomarkers used to measure it—including epigenetic patterns, inflammatory signals, protein profiles, and physiological performance—do not always provide the same picture. A treatment that makes one molecular clock appear younger may not necessarily reduce disease or improve survival. For that reason, the next stage of the field will depend on carefully designed studies, long-term monitoring, improved measurement technologies, and collaboration among basic scientists, clinical investigators, regulators, and commercial developers.

Vadim Gladyshev, Executive Chair of ARDD and Professor of Medicine at Harvard University, said that aging biology has become one of biomedical science’s most promising frontiers, while emphasizing the need to connect fundamental discoveries with interventions that improve healthspan. Morten Scheibye-Knudsen, Co-Chair of ARDD and Associate Professor at the University of Copenhagen, described the conference’s move to Boston as a new chapter for the event, placing it within one of the world’s strongest biomedical innovation ecosystems. He also pointed to the field’s increasing emphasis on translation, as discoveries in aging biology are increasingly being evaluated according to their potential to become medicines rather than remaining isolated laboratory findings.

ARDD 2026 will be anchored by Tier 1 sponsors Insilico Medicine and Eli Lilly, with the McKinsey Health Institute serving as Sole Knowledge Partner. Tier 3 sponsors include AbbVie, AniVC, AstraZeneca, BioAge Labs, Biocytogen, Cambrian Bio, Cyclarity Therapeutics, Dior, GlycanAge, Gordian Biotechnology, Human Longevity, the Institute for Healthier Living Abu Dhabi, LongeVC, Maxwell Biosciences, Nestlé, Tally Health, and TruDiagnostic. Synaro Capital, The Cat Health Company, and PranaGen Bioscience are supporting the meeting as Tier 4 sponsors, while Estée Lauder, Morgan Stanley, the Intrinsic Capacity Frailty & Sarcopenia Research Conference for Healthy Longevity, and QuadraScope are listed as Tier 5 sponsors. The breadth of participation reflects the growing financial and industrial interest in therapies that could address the biological drivers of age-related decline.

Alex Zhavoronkov, Co-Chair of ARDD and CEO of Insilico Medicine, said Church has repeatedly helped move ideas once regarded as speculative toward serious scientific and technological possibility. His presence captures the conference’s larger purpose: connecting ambitious biological concepts with the researchers, companies, and investors capable of testing and developing them. Now in its 13th year, the Aging Research & Drug Discovery Meeting describes itself as the world’s largest meeting dedicated to aging and longevity biotechnology. The 2026 gathering will also receive support from the Nordic Aging Society, a nonprofit scientific organization focused on aging research and collaboration across the Nordic region and beyond. Organizers are inviting media inquiries and interview requests through ardd@pharma.ai, while additional information is available at agingpharma.org.

Subject of Research: Aging research, longevity biotechnology, genomics, cellular reprogramming, gene therapy, and the development of therapies targeting age-related decline.

Article Title: George Church to Deliver Featured Address at ARDD 2026 on the Future of Longevity Science

News Publication Date: August 18, 2026

Web References: agingpharma.org

Image Credits: ARDD 2026

Keywords: George Church, ARDD 2026, aging research, longevity science, longevity biotechnology, genomics, gene therapy, cellular reprogramming, synthetic biology, healthspan, Harvard University, Insilico Medicine, drug discovery

Typically, antibodies serve as crucial tools in both biology and medicine due to their highly selective nature, enabling them to bind precisely to specific target molecules. However, a substantial limitation of conventional antibodies is their inability to function effectively within the cellular environment. This has hindered the exploration and understanding of vital biological processes that occur inside cells. Intrabodies present a promising solution to this dilemma, as they are designed to operate within living cells. Yet, their development has historically faced challenges, particularly as antibodies frequently misfold or lose their functional capabilities when introduced into cellular settings.

The research team, led by Professor Hiroshi Kimura from the Institute of Integrated Research at the Institute of Science Tokyo, Japan, collaborated with esteemed colleagues from various institutions, including Colorado State University and Kyushu University. Their collaborative efforts culminated in a breakthrough methodology published in the esteemed journal Science Advances. The core of their advancement lies in a unique design strategy that intelligently alters the structural framework of antibodies while preserving the integrity of their antigen-binding regions.

The AI-driven pipeline developed by this research team keeps the critically important target-binding regions intact, while judiciously modifying the surrounding framework. This approach ensures that the resulting intrabodies are not only able to fold correctly but also maintain their stability inside the cellular milieu without sacrificing their binding specificity. The team meticulously tested approximately 26 previously established antibody sequences, with a remarkable success rate: 19 of those were successfully repurposed into functional intrabodies. Significantly, 18 out of the 19 had earlier been ineffective as intrabodies when conventional methods were employed.

This remarkable outcome underscores a pivotal revelation in the realm of protein design; many antibodies that were previously thought to be unfit for intracellular application can be rendered functional through innovative AI-guided redesign strategies. The transformative potential of artificial intelligence in optimizing antibody structures within cellular environments not only enhances their efficacy but also opens avenues for a more nuanced understanding of cellular dynamics as influenced by these intrabodies.

One of the primary focuses of the study was intrabodies specifically targeting modifications in histone proteins—vital components that play indispensable roles in DNA packaging and gene regulation. These histone modifications serve as crucial markers, providing insights into gene activity. However, traditional labeling techniques to study these modifications often fall short, leaving researchers with gaps in their knowledge. The newly designed intrabodies possess the ability to accurately detect and report on these histone modifications, responding dynamically to changes within cellular environments, thereby illuminating the complexities of gene regulation in real-time.

Further validation of the redesigned intrabodies confirmed their remarkable stability and functionality within living cells. The experimental results demonstrated not only their solubility but also their high specificity for target molecules, which is imperative for accurate biological research. The redesigned molecules exhibited consistent and predictable behavior even under varying cellular conditions, showcasing the reliability of this new research tool. Such characteristics are critical for advancing our understanding of myriad biological functions regulated by histone modifications and other intracellular processes.

The implications of this research extend far beyond basic science. By harnessing the capabilities of AI, the researchers aim to streamline the development of intrabodies, making it a faster, cheaper, and more accessible process for researchers worldwide. As the repository of antibody sequence data continues to grow, the potential to convert existing antibodies into functional intracellular probes could revolutionize diagnostics, fluorescence imaging, and therapeutic strategies in various biomedical applications. The implications for clinical research are profound, suggesting that this AI-driven approach could become a cornerstone of future therapeutic research, enabling scientists to tackle complex disease mechanisms with unprecedented precision.

In conclusion, this innovative study demonstrates that merging artificial intelligence with the nuanced understanding of protein engineering yields a powerful combination for biomolecular research. The team has set a new gold standard for intrabody development, showcasing the transformative potential of AI technologies in modern biotechnology. This research not only provides the foundation for future advancements in the field but also emphasizes the critical role of interdisciplinary collaboration in driving scientific progress forward.

The path ahead is laden with opportunities as researchers look to refine and expand upon these AI-assisted strategies, ultimately aiming to elucidate the intricate networks of biological interactions that govern cellular function and disease processes. By continuing to leverage the capabilities offered by AI and machine learning, the scientific community is poised to unlock new dimensions in the realm of protein design and intracellular research, forging ahead toward a future marked by innovation and discovery.

Subject of Research: Cells
Article Title: AI-assisted protein design to rapidly convert antibody sequences to intrabodies targeting diverse peptides and histone modifications
News Publication Date: 2-Jan-2026
Web References: Science Advances
References: DOI: 10.1126/sciadv.adx8352
Image Credits: Institute of Science Tokyo (Science Tokyo)

Keywords

Health and medicine, Biomedical engineering, Artificial intelligence, Immunology, Antibodies

The impetus behind these projects lies in the recent surge of artificial intelligence capabilities that have dramatically enhanced the ability to predict the three-dimensional structures of proteins with unprecedented accuracy. By leveraging this structural understanding, scientists can now design novel proteins tailored for specific functionalities, addressing longstanding challenges in biomanufacturing, healthcare, and materials science. NSF’s investment under the Use-Inspired Acceleration of Protein Design (USPRD) program emphasizes not just theoretical advances but the translation of these innovations into real-world applications that can stimulate the U.S. bioeconomy and promote sustainable manufacturing solutions.

One of the thrusts spearheaded at UC Davis targets the challenging synthesis of acrylates, a class of molecules extensively utilized in manufacturing paints, plexiglass, and super-absorbent materials. The conventional production of acrylates is often costly and environmentally taxing. In collaboration with biotech firm Arzeda, based in Seattle, UC Davis researchers aim to engineer bespoke enzymes capable of catalyzing acrylate synthesis more rapidly, affordably, and at scale. This enzyme-centric approach is anticipated to disrupt traditional chemical manufacturing paradigms by offering biocatalytic pathways that are both efficient and sustainable. The leadership of this initiative includes Program Director Ashley Vater from the UC Davis Genome Center alongside Professor Justin Siegel, whose expertise spans chemistry and biochemistry disciplines, further reinforcing UC Davis’s commitment to multidisciplinary integration in addressing biosynthetic challenges.

Complementing the technical objectives of acrylate biosynthesis is a robust educational endeavor. UC Davis is set to expand its acclaimed Design to Data (D2D) program, a pioneering student training initiative dedicated to hands-on protein design experiences. This expansion is strategically aligned with the broader mission to democratize access to protein engineering education, equipping the next generation of bioengineers with practical tools and research opportunities. Such educational outreach is critical in cultivating a skilled workforce capable of advancing the frontiers of synthetic biology and biotechnology across academic and industrial sectors.

In parallel, the second major project addresses a critical gap in infant nutrition by striving to replicate complex sugars found in human milk, known scientifically as human milk oligosaccharides (HMOs). HMOs play a vital role in infant health and development, fostering immune protection and gastrointestinal maturation. However, their intricate structure has historically made large-scale synthesis challenging and expensive. UC Davis researchers, in partnership with Novozymes—a global leader in enzyme innovation based in Davis—are integrating advanced enzyme engineering, machine learning algorithms, and cell-free protein synthesis platforms to optimize HMO production. This confluence of cutting-edge biotechnological techniques aims to enhance the availability and affordability of HMOs for infant formula, addressing public health needs while expanding the toolkit for enzyme systems with broad commercial utility.

The application of machine learning within this project exemplifies the transformative impact of AI on enzyme design. By iteratively refining enzyme function and stability in silico, researchers can drastically shorten development cycles and improve catalytic efficiency. Integrating cell-free protein synthesis allows rapid prototyping without the constraints of living cells, offering a flexible and scalable system to characterize and evolve enzymes under diverse conditions. Together, these technological innovations not only advance HMO synthesis but also set a precedent for producing other complex biomolecules relevant to human health and nutrition.

Both UC Davis initiatives underscore a larger vision promulgated by NSF spokesperson Erwin Gianchandani, who highlighted that the USPRD program is a strategic investment aimed at sustaining American leadership in biotechnology amidst intensifying international competition. By combining AI, enzyme engineering, and multidisciplinary collaboration, these projects embody efforts to unlock new pathways in biomanufacturing and generate advanced materials vital to a spectrum of critical industries—from healthcare to environmental sustainability.

The NSF funding catalyzes opportunities for UC Davis to build extensive national collaborations, drawing on expertise across biochemistry, chemical engineering, computer science, and molecular biology to accelerate innovation pipelines. Such cross-disciplinary integration is increasingly recognized as essential to realizing the full potential of synthetic biology and AI-enabled design approaches. Moreover, these advancements are expected to have immediate impacts, fostering growth in the bioeconomy while also contributing to workforce development through educational programs like Design to Data.

Critically, these projects do not operate in isolation. They reflect a concerted national effort to transition AI-based protein design from academic proof-of-concept stages into practical, scalable technologies. The goal is to overcome longstanding hurdles in enzyme engineering such as limited catalytic diversity, instability under industrial conditions, and the complexity of translating molecular designs into manufacturable products. By addressing these challenges head-on, the NSF USPRD initiative lays the groundwork for wide-reaching applications including sustainable chemical production, improved therapeutics, and enhanced nutritional products.

UC Davis’s dual role as a research and education hub amplifies the ripple effects of these projects. On the research front, leaders like Professor Siegel are driving forward technical innovation, while on the educational side, the expansion of hands-on training programs ensures that thousands of students nationwide gain meaningful experience in AI-driven protein engineering. This comprehensive ecosystem fosters a virtuous cycle of innovation, knowledge dissemination, and workforce preparedness that is vital for maintaining competitive advantage in the rapidly evolving biotech landscape.

In conclusion, the infusion of NSF funding into these two UC Davis projects heralds a new era of protein design empowered by AI, representing an ambitious and timely response to global biotechnology challenges. By advancing enzyme technologies for the synthesis of economically and medically significant molecules such as acrylates and HMOs, these initiatives are poised to deliver wide-ranging impacts that extend well beyond the laboratory. As the fields of artificial intelligence and synthetic biology continue to coalesce, projects like these will define the future of sustainable manufacturing, health innovation, and bioengineering education.

Subject of Research: AI-driven protein and enzyme design for industrial and health applications.

Article Title: (Not explicitly provided in the source material)

News Publication Date: (Not explicitly provided in the source material; funding announced August 7)

Web References: https://www.nsf.gov/tip/updates/nsf-invests-nearly-32m-accelerate-novel-ai-driven-approaches

References: (Not explicitly provided)

Image Credits: (Not provided)

Keywords: Enzyme design, Biotechnology, Bioengineering, Artificial intelligence